Study of Dentoxol® Mouthrinse for Oral Mucositis

NCT02885376 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2018-12-21

No results posted yet for this study

Summary

The primary objective of this study is to determine the efficacy of Dentoxol® mouthrinse in reducing the severity of oral mucositis secondary to radiation therapy for head and neck cancer.

Conditions

  • Oral Mucositis

Interventions

DEVICE

Dentoxol

Mouthrinse

DEVICE

Placebo

Mouthrinse

Sponsors & Collaborators

  • Ingalfarma SpA

    lead INDUSTRY

Principal Investigators

  • Sebastián Sole · Clinica IRAM

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2018-04-30
Completion
2018-08-31

Countries

  • Chile

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02885376 on ClinicalTrials.gov